Leukoencephalopathies are disorders that primarily affect the white matter of the central nervous system (CNS). It contains acquired leukoencephalopathy[@b1][@b2][@b3] (leukoencephalopathy induced by ischemia, hypoxia, intoxication, infection, traumatic brain injuries, etc.), genetic leukoencephalopathy[@b4][@b5][@b6] (such as metachromatic leukodystrophy, globoid cell leukodystrophy, X-linked adrenoleukodystrophy, etc.) In addition, it also contains some mitochondrial diseases, cerebral cortical degenerative disorders, and so on. Clinically, after considering clinical history, symptoms and brain MRI features, doctors may be able to give a diagnosis for acquired leukoencephalopathies. However, leukoencephalopathy is a disease with high clinical heterogeneity and may involve in multiple genes, it is difficult even for experienced neurologists to make definite diagnosis[@b7][@b8][@b9]. Therefore, we are in urgent need of finding an efficient, economical, and practical method for diagnosing leukoencephalopathies.

In recent years, gene sequencing technology got amazing advancement. Whole exome sequencing (WES) represents a significant breakthrough in clinical genetic as a powerful tool for etiological discovery in many kinds of disorders[@b10]. Benefited from the WES technology, a lot more pathogenic genes have been found and many types of diseases have been identified[@b11][@b12][@b13]. Innovative application of new technologies is one of the major factors driving advances in medical science, most clinical applications of next-generation sequencing (NGS) concentrate on known and potential candidate genes to generate clear reports and finally promote clinical diagnosis[@b14][@b15][@b16][@b17][@b18]. Targeted gene capture and massively parallel sequencing (MPS) have been shown to be an effective technique for genetic analysis and have already led to many exciting discoveries[@b19][@b20]. To make a clear or definite diagnosis for those patients with leukoencephalopathies, we designed a custom probe library containing 118 genes reported to be associated with leukoencephalopathies ([Table 1](#t1){ref-type="table"}).

We embarked on this study to assess the utility and effectiveness of targeted capture and MPS technology in 49 Chinese leukoencephalopathy patients. To our knowledge, this is the first study to use targeted gene capture and sequencing for leukoencephalopathies. 40.8% positive rate confirmed that the implementation of this method can accelerate diagnosis, reduce overall cost, and expand our knowledge of the genetic and clinical spectra of leukoencephalopathies.

Results
=======

Demographic and Clinical characteristics of the total 49 patients
-----------------------------------------------------------------

We summarized the clinical characteristics of the total 49 patients enrolled in this study and found 39 are male and 10 are female. The age at onset of symptoms varied from 20 days to 7 years and the average onset age was almost 1.2 years. The main neurologic complaint of these patients include developmental delay/regression (27/49, 55.1%), epilepsy (15/49, 30.6%), weakness (7/49, 14.3%), ataxia (5/49, 10.3%) and dystonia (5/49, 10.3%). The severity of the disease course is reflected in the developmental milestones achieved. Two patients have suspected familial clustering. One has been diagnosed as adrenoleukodystrophy by gene testing. His mother's elder brother had the same clinic feature and MRI findings, and died at his age of 12. The other one has been diagnosed as mitochondrial complex I deficiency, and his elder sister has a similar brain MRI changes without significant neurological disease manifestation. The wide spectrum of MRI findings was noted in the study. Abnormality in periventricular, subcortical white matter and cerebellar hemisphere were common. Lumbar puncture and CSF analysis were performed in 19 patients. None of them had a positive result.

Twenty patients were identified pathogenic mutations in this study, and their demographic and clinical characteristics were shown in [Table 2](#t2){ref-type="table"}. However, more than half (29/49, 59%) of patients in our study did not reach the diagnosis.

Targeted capture and MPS sequencing results
-------------------------------------------

In this study, 40.8% (20/49) exhibited pathogenic mutations, in which fifteen pathogenic variation sites have not yet been reported in HGMD. The proportion of each kind of disease diagnosed in our study is shown in [Fig. 1](#f1){ref-type="fig"}. The most common disease diagnoses were metachromatic leukodystrophy (4/49, 8.2%), mitochondrial diseases (3/49, 6.1%), vanishing white matter disorder (3/49, 6.1%) and megalencephalic leukoencephalopathy with subcortical cysts (3/49, 6.1%). Details genetic data were summarized in [Table 3](#t3){ref-type="table"}.

Discussion
==========

With the widespread use of imaging examinations in nervous system diseases, finding the pathogeny of cerebral white matter lesions becomes an important clinical clue for neurologists. Because of the strong heterogeneity of hereditary leukoencephalopathy, it is difficult even for experienced doctors to make a definitive diagnosis, and a multistep process is often needed[@b7][@b21]. Currently, routine clinical diagnostic tests for leukodystrophy often consist of screening for genes on the basis of ethnic origin, MRI features, family history, personal history and findings from physical examinations[@b22]. In China, the problem seems more serious, with the lack of a referral system, many patients and their families wasted valuable time, finances, and medical resources seeing various doctors and getting repeat examinations in search of a correct diagnosis. Some patients who could even be cured missed the opportunity for effective treatment. However, due to the high cost of Sanger sequencing for the long list of candidate genes, more effective genetic screening methods are needed.

In recent years, targeted capture and MPS technologies have been widely used in clinical practice and have got satisfactory results[@b15][@b23][@b24][@b25][@b26][@b27][@b28]. To this end, we designed the gene panel contains 118 genes which are reported to be associated with leukoencephalopathies, not only contains genes associated with genetic leukoencephalopathy, but also mitochondrial disease, cerebral cortical degenerative disorders, etc. associated genes. Then we designed the probe library and performed this study to assess the utility and effectiveness of targeted capture and MPS in diagnosing leukoencephalopathy patients.

In our study, 40.8% (20/49) of the patients detected pathogenic mutations, which is higher than that of other commercially available chips. In our department, the positive rate of a mitochondrial disease chip is only 9.5%, and that of a metabolic disease chip is 16% (data not shown). These differences may be explained by the variety of pathogenic mutations and lack of a specific clinical phenotype associated with these disorders. Moreover, the results achieved using the leukoencephalopathy probe library may be explained by the distinctive brain MRI patterns that characterize leukoencephalopathy that was seen in most of the patients, providing a guide in the diagnostic process. In addition, patients had been thoroughly examined before the screening for leukoencephalopathy-associated genes, and other secondary causes were already excluded.

Among the result, one patient (case 19) was diagnosed with Zellweger syndrome with *PEX6* gene compound heterozygous mutations, *PEX6* gene mutation is reported to be associated with Peroxisome biogenesis disorder 4A/B[@b29][@b30]. The patient in our study was a 5.9-year-old girl exhibiting mental and motor retardation for 5 years, and with deterioration for 3 months (Clinical features and auxiliary examinations are included in [Table 2](#t2){ref-type="table"}). Brain MRI showed symmetrically increased signal intensity in T2-weighted images with gadolinium enhancement in the posterior limbs of the internal capsules ([Fig. 2](#f2){ref-type="fig"}). There was no diffuse restriction or gadolinium enhancement in the periventricular area and deep white matter, similar to the features of X- ALD[@b31][@b32]. However, this is a female and the *ABCD1* gene in this patient exhibited a normal sequence and gene dosage. Given the diagnostic uncertainty, targeted capture and MPS were performed. Molecular testing identified *PEX6* gene compound heterozygous mutations, supporting the Zellweger spectrum disorder diagnosis in this patient. Genetic analysis showed that the two mutation sites were respectively inherited from the parents. The result showed us the effectiveness of this targeted capture and MPS method for the diagnosis of leukoencephalopathies.

The targeted capture and MPS method can not only diagnose genetic leukoencephalopathies, but also can make the diagnosis of mitochondrial diseases with white matter abnormal as the primary imaging changes. In our study, three of our patients had pathogenic gene mutations associated with mitochondrial complex I deficiency. Our team was the first to report leukoencephalopathy associated with mitochondrial complex I deficiency due to a novel mutation in the *NDUFAF1* gene (c.278A \> G; c.247G \> A)[@b33]. Mitochondrial complex I deficiency is the most frequent cause of respiratory chain defects in childhood, which accounts for various clinical presentations[@b34][@b35]. As the report, mutations have been described in 28 of these, including the 7 mitochondrial genes and 21 nuclear genes. Brain lesions caused by mitochondrial complex 1 deficiency are usually located in the brainstem, periaqueductal gray matter, the thalamus, etc. While, diffuse supratentorial leukoencephalopathy involving the deep lobar white matter may also occur in patients with mitochondrial complex 1 deficiency, especially in patients with nuclear DNA (nDNA) mutations. Some patients were available with abnormal white matter containing cysts in FLAIR sequences, and other patients may have notably hyperintense on T2 and very hypointense on T1 weighted images, suggesting cysts[@b33][@b36]. Therefore, containing pathogenic genes associated with mitochondrial diseases can promote the diagnosis of patients with leukoencephalopathies.

The patients in our study came from six provinces in central-south China. Therefore, the results may represent the specific disease incidence in this region. When clinicians encounter children with prominent cerebral white matter lesions that can't be explained by a certain disease, application of leukoencephalopathy probe library gene screening may be useful. Targeted capture and MPS can detect multiple candidate genes at the same time in a fast, cost-effective way, and can facilitate clinical diagnosis. Moreover, by reaching a definitive diagnosis for children with leukoencephalopathy, we can better judge the prognosis for patients and provide genetic counseling.

In summary, our data demonstrate that the use of targeted capture and MPS technology coupled with NGS has great promise as a tool for screening leukoencephalopathy-related genes for diagnostic purposes in patients. At the same time, genetic testing results combined with detailed clinical phenotypes help us expand our knowledge of the clinical spectra of each type of leukoencephalopathy. This method enables clinicians to identify leukoencephalopathy even the clinical performance is not typical. Moreover, the entire process of targeted capture, sequencing, analysis, and parental analysis was rapid (requiring only 10 days for up to 12 patients).

While targeted genomic capture and MPS technology also has its limitation, it can only identify the known pathogenic mutations. With the development of gene testing technology, a lot more pathogenic mutations will be detected, so the panel should be renewed with the latest findings, and the patients with negative results of genetic testing can be re-tested using the newest panel. With the fast development of NGS sequencing, the price will be more accessible, we can choose whole exome sequencing (WES) if the targeted analysis is unrevealing, or we can directly choose the WES technology. WES will be the inevitable trend, but under the condition of most countries and before this come true, our panel with cheap price, fast testing speed and strong pertinence, still have the irreplaceable advantage. Thus, we expect that this method can serve as an inspirational starting point. This technology will enable us to conduct straightforward, comprehensive screening for more known leukoencephalopathy-related genes, and to expand and redefine the genetic and clinical spectra of leukoencephalopathies.

Methods
=======

Patients
--------

From December 2013 to December 2015, 49 patients (10 female and 39 male) were recruited into our cohort. All of these patients have white matter damage as the most obvious imaging characteristic. Two pediatric neurologists and one radiologist made the decisions together, according to the medical history, family history, physical examination and magnetic resonance imaging (MRI), patients with obvious ischemia, hypoxia, intoxication or infection was not enrolled in our cohort. The study design was approved by institutional review board of Xiangya Hospital of Central South University, China. And the study procedures were carried out in accordance with the requirements of regulations and procedures regarding human subject protection laws. After obtaining informed consent from all participants, we recorded the clinical features of the patients and collected blood samples from the patients and their parents via venipuncture.

Panel design
------------

We searched the OMIM and HGMD professional databases for genes which are reported to be associated with leukoencephalopathies. A custom-based targeted Agilent SureSelect pull-down panel was designed with the SureDesign program (Agilent Technologies). This target was 0.7 Mb of sequence from the coding exons (GRCh37/hg19 human reference sequence, UCSC Genome Browser) of 118 related candidate or known genes.

Genetic testing
---------------

Genomic DNA was isolated from peripheral blood leukocytes (Promega, Beijing). Target-fragments are capture by SureDesign target enrichment kit (Agilent, Santa Clara, CA) and high throughput sequencing by HiSeq2500 sequencer (Illumina Inc, San Diego, CA) were conducted in house. Overall, 49 samples were sequenced pre lane and the mean depth is 583X.

Bioinformatic Pipeline
----------------------

For the quality control, the Cutadapt and FastQC were used to remove 3′-/5′- adapters andlow-quality reads, respectively. The clean reads were mapped to the reference human genome using the BWA (Burrows--Wheeler Aligner) program with at most two mismatches. The alignment files (bam) were generated with SAM tools and the reads of low mapping quality (\<Q30) were filtered out. Clonal duplicated reads that may be derived from PCR artifacts were removed using Picard Tools by default parameters. Short read alignment and annotation visualization were performed using the IGV (Integrative Genomics Viewer). The percentage of alignment of the clean read to the exome regions was obtained using our custom Perl scripts on the base of alignment files. SNVs and indels were detected by GATK (Genome Analysis ToolKit). Comprehensive annotation of all of the detected SNVs and indels were annotated by ANNOVAR, including function implication (gene region, functional effect, mRNA GenBank accession number, amino acid change, cytoband, etc.) and allele frequency in 1000 Genomes, ExAc. Damaging missense mutations were predicted by SIFT, PolyPhen-2 and MutationTaster.
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![The etiology composition of Leukoencephalopathies in this cohort.\
(**A**) Flow diagram to exhibit workflow and results in this cohort. (**B**) Pie chart to exhibit the etiology composition of leukoencephalopathies in this cohort. MLD: metachromatic leukodystrophy, VWM: vanishing white matter disorder, AD: Alexander disease, PMD: Pelizaeus-Merzbacher Disease, X-ALD: X-linked adrenoleukodystrophy, MLC: megalencephalic leukoencephalopathy with subcortical cysts, GLD: globoid cell leukodystrophy.](srep35936-f1){#f1}

![Brain MRI changes of case19 and the electropherogram of Sanger sequencing of the compound mutation of PEX6 gene.\
On FLAIR and T2-weighted sequences, abnormal hyperintense is seen in the splenium of corpus callosum, adjacent parieto-occipital white matter, posterior limbs of internal capsules extending to centrum oval, thalami and upper cervical spinal cord. Gadolinium enhancement is visible on T1-weighted sequences in internal capsules and anterior commissure. The child detected missense mutation on chr6:42932599(c.2735C \> T) and nonsense mutation on chr6:42937459(c.1313insT), which were respectively inherited from the parents. (**a**) Brain MRI T1-weighted image. (**b**) Brain MRI T2-weighted image. (**c**) Brain MRI flare image. (**d**) Brain MRI enhanced image. (**e--g**) The electropherogram of Sanger sequencing of the probands (**e**), the father (**f**) and the mother (**g**) on chr6:42932599. (**h--j**) The electropherogram of Sanger sequencing of the probands (**h**), the father (**i**) and the mother (**j**) on chr6:42937459.](srep35936-f2){#f2}

###### 118 genes targeted fo capture and sequencing.

  Gene         NM number     Chromosome   Exons    Gene      NM number     Chromosome   Exons
  ---------- -------------- ------------ ------- --------- -------------- ------------ -------
  ABAT        NM_001127448     chr16       16       FTL      NM_000146       chr19        4
  ABCD1        NM_000033        chrX       10      FUCA1     NM_000147        chr1        8
  ACOX1        NM_004035       chr17       14      GALC      NM_000153       chr14       17
  ADGRG1      NM_001290143     chr16       14       GAN      NM_022041       chr16       11
  AIMP1       NM_001142416      chr4        7      GCDH      NM_000159       chr19       12
  ALDH3A2     NM_001031806     chr17       11      GFAP     NM_001242376     chr17        7
  AMACR        NM_014324        chr5        5      GJA1      NM_000165        chr6        2
  APP         NM_001136129     chr21       15      GJB1     NM_001097642      chrX        2
  ARSA        NM_001085428     chr22        8      GJC2      NM_020435        chr1        2
  ARSE         NM_000047        chrX       11     HEPACAM    NM_152722       chr11        7
  ASPA         NM_000049       chr17        6      HSPD1     NM_199440        chr2       12
  ATP13A2     NM_001141974      chr1       27      HTRA1     NM_002775       chr10        9
  AUH          NM_001698        chr9       10     L2HGDH     NM_024884       chr14       10
  BCAP31      NM_001256447      chrX        8      LMNB1    NM_001198557      chr5       11
  BCS1L       NM_001257344      chr2        8      MCCC1     NR_120640        chr3       19
  C19orf12    NM_001256047     chr19        3       MGP      NM_000900       chr12        4
  CLCN2       NM_001171088      chr3       23      MLC1      NM_139202       chr22       12
  COASY       NM_001042529     chr17       10      MLYCD     NM_012213       chr16        5
  COX15        NM_004376       chr10        9      MPV17     NM_002437        chr2        8
  COX6B1       NM_001863       chr19        4     NDUFA1     NM_004541        chrX        3
  CP           NR_046371        chr3       18     NDUFA10    NM_004544        chr2       10
  CSF1R        NM_005211        chr5       22     NDUFA11   NM_001193375     chr19        4
  CTC1         NR_046431       chr17       22     NDUFA12    NM_018838       chr12        4
  CYP27A1      NM_000784        chr2        9     NDUFA2    NM_001185012      chr5        3
  DARS2        NM_018122        chr1       17     NDUFA9     NM_005002       chr12       11
  DCAF17      NM_001164821      chr2       12     NDUFAF1    NR_045620       chr15        6
  DDC         NM_001242890      chr7       10     NDUFAF2    NM_174889        chr5        4
  DLD         NM_001289752      chr7       13     NDUFAF3    NM_199074        chr3        5
  EIF2B1       NM_001414       chr12        9     NDUFAF4    NM_014165        chr6        3
  EIF2B2       NM_014239       chr14        8     NDUFB3    NM_001257102      chr2        4
  EIF2B3      NM_001166588      chr1       10     NDUFS1     NM_005006        chr2       19
  EIF2B4       NM_015636        chr2       13     NDUFS2    NM_001166159      chr1       13
  EIF2B5       NM_003907        chr3       16     NDUFS3     NM_004551       chr11        7
  ERCC6        NM_000124       chr10       21     NDUFS4     NM_002495        chr5        5
  ERCC8        NM_000082        chr5       12     NDUFS6     NM_004553        chr5        4
  ETHE1        NM_014297       chr19        7     NDUFS7     NM_024407       chr19        8
  FA2H         NM_024306       chr16        7     NDUFS8     NM_002496       chr11        7
  FAM126A      NM_032581        chr7       11     NDUFV1     NM_007103       chr11       10
  FASTKD2     NM_001136193      chr2       12     NDUFV2     NM_021074       chr18        8
  FKTN        NM_001079802      chr9       11     NOTCH3     NM_000435       chr19       33
  FOLR1        NM_016729       chr11        4      NUBPL     NM_025152       chr14       11
  FOXRED1      NM_017547       chr11       11      PANK2     NM_153640       chr20        7
  PC          NM_001040716     chr11       23     SAMHD1     NM_015474       chr20       16
  PEX1        NM_001282678      chr7       24      SCP2     NM_001007250      chr1        4
  PEX10        NM_153818        chr1        6      SDHA      NM_004168        chr5       15
  PEX12        NM_000286       chr17        3     SDHAF1    NM_001042631     chr19        1
  PEX13        NM_002618        chr2        4     SLC16A2    NM_006517        chrX        6
  PEX16        NM_004813       chr11       11     SLC17A5    NM_012434        chr6       11
  PEX26       NM_001199319     chr22        5      SOX10     NM_006941       chr22        4
  PEX5        NM_001131025     chr12       16      SUMF1     NM_182760        chr3        9
  PEX6         NM_000287        chr6       17      SURF1     NM_003172        chr9        9
  PHYH        NM_001037537     chr10        8     TRAPPC9   NM_001160372      chr8       23
  PLA2G6       NM_003560       chr22       17      TREM2    NM_001271821      chr6        4
  PLP1        NM_001305004      chrX        7      TREX1     NM_007248        chr3        2
  POLR3A       NM_007055       chr10       31     TUBB4A    NM_001289131     chr19        4
  POLR3B      NM_001160708     chr12       28      TUFM      NM_003321       chr16       10
  PSAP         NM_002778       chr10       14      TYMP     NM_001113756     chr22        9
  RNASET2      NM_003730        chr6        9     TYROBP     NM_003332       chr19        5
  RPIA         NM_144563        chr2        9      WDR45     NM_007075        chrX       12

###### Demographic and clinical feathers of patients with pathogenic mutations.

  Case   Diagnosis                            Sex, age (years)   clinical manifestation                                  Personal History                                Developmental milestones                                                                        family history                                                                              physical examination                                              Auxiliary examinations                                                                                                                                                                                                                           Brain MRI
  ------ ------------------------------------ ------------------ ------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1      mitochondrial complex I deficiency   Male, 0.9          Motor retardation                                       G2P2 full-term normal delivery BW:3.05 kg       bristling up head: 4M sit: incapable call mom: 10M                                              His elder sister (4Y) has a similar brain MRI changes without obvious neurologic symptoms   HC: normal; Hypertonia; hyper-reflexia; Strephexopodia;           Elevated creatine kinase level(297 U/L; normal, \<190 U/L); EEG (10M): normal; VEP, BAEP: normal                                                                                                                                                 MRI (11M): Diffuse and symmetric abnormal signal in central and subcortical white matter, hyperintense in the T2 and FLAIR sequences and were hypointense in T1-weighted sequence.
  2      mitochondrial complex I deficiency   Male, 0.4          Mental and motor retardation; seizure;                  G1P1 full-term normal delivery BW:2.0038 kg     bristling up head: incapable                                                                    normal                                                                                      HC: normal; Hypertonia; Tiptoe;                                   Increased actate level (4.7 mmol/L; normal, 0.5--2.2 mmol/L); Elevated creatine kinase level (789.7 U/L; normal, \<190 U/L); EMG: moderate peripheral demyelinating sensorimotor neuropathy; EEG: slow background; VEP: normal; BAEP: abnormal   MRI (5M): symmetry abnormal signal in bilateral cerebellar hemisphere, hyperintense in the T2 and FLAIR sequences and were hypointense in T1-weighted sequence.
  3      mitochondrial complex I deficiency   Female, 3.1        Mental and motor retardation;                           G1P1 full-term normal delivery BW:2.5 kg        bristling up head: 6M; sit: 1Y; walk without help: incapable; call mom: 14M                     normal                                                                                      HC: normal; Hypertonia; Horizontal nystagmus                      Actate level: normal; Elevated creatine kinase level (320.0 U/L; normal, \<190 U/L); EMG: peripheral demyelinating sensorimotor neuropathy;                                                                                                      MRI (2.8Y): symmetry abnormal signal in Periventricular and basal ganglia, hyperintense in the T2 and FLAIR sequences and were hypointense in T1-weighted sequence.
  4      MLD                                  Male, 2.5          extremities weakness; Motor regression;                 G2P2 full-term normal delivery BW:2.9 kg        bristling up head: 3^+^M; sit without help: 7M walk without help: 12M call mom: 12M             normal                                                                                      HC: normal Amyasthnia (1Y); Hypertonia(2Y); Hyper-reflexia(2Y);   EMG: slow sensory and motor nerve conduction velocities; VEP: P100 latency increased; BAEP: latency prolonged; Brain CT: hypointense in Periventricular;                                                                                         MRI (2.4Y): abnormal signal in periventricular, "tigroid" symptom in T2-weighted sequence;
  5      MLD                                  Femal, 2.4         extremities weakness; Mental regression;                G1P1 full-term Cesarean delivery BW:3.9 kg      bristling up head: 3M sit without help: 7M walk without help: 15M call mom: 13M                 normal                                                                                      HC: normal; Amyasthnia (1.7Y); Hypertonia (2.2Y);                 Elevated creatine kinase level (337.5 U/L; normal, \<190 U/L); EMG: slow sensory and motor nerve conduction velocities, demyelination and axonal damage; EEG: high voltage and slow wave;                                                        MRI (2.4Y): abnormal signal in periventricular, posterior limbs of internal capsules, hyperintense in the T2 and FLAIR sequences and were hypointense in T1-weighted sequence.
  6      MLD                                  Male, 2.5          Mental regression;                                      G2P2; full-term; Cesarean delivery; BW:3.1 kg   bristling up head:3^+^M; sit without help: 6^+^M walk without help:14M; call mom: 12M;          normal                                                                                      HC: normal; Hypertonia (2.1Y);                                    EMG: demyelination and axonal damage; EEG: high voltage and slow wave, irregular sharp wave in frontal area;                                                                                                                                     MRI (2Y): abnormal signal in central and subcortical white matter, hyperintense in the T2 and FLAIR sequences and were hypointense in T1-weighted sequence.
  7      MLD                                  Male, 2.1          Mental regression;                                      G2P1 full-term normal delivery BW:2.9 kg        bristling up head:3M; sit without help: 7M; walk without help:15M; call mom: 12M;               normal                                                                                      HC: normal; Amyasthnia (1.9Y);                                    EMG: slow sensory and motor nerve conduction velocities; VEP: P100 latency increased; BAEP: latency prolonged;                                                                                                                                   MRI (2Y): abnormal signal in the periventricular and the central white matter, "leopard skin"-like change in T2-weighted sequence
  8      VWM                                  Male, 3.5          Seizure; Mental and motor regression;                   G3P1 full-term normal delivery BW:3.2 kg        bristling up head:3M sit without help: 7M walk without help:13M call mom: 12M                   normal                                                                                      HC: normal Hypertonia Ataxia                                      EEG(3Y): Paroxysmal slow wave in sleep stage;                                                                                                                                                                                                    MRI (3.5Y): diffused abnormal signal in the central deep and subcortical white matter, hyperintense in the T2 sequences, hypointense inT1 and FLAIR sequences; MRS: normal.
  9      VWM                                  Femal, 1.2         Seizure; hypotonia                                      G1P1 full-term Cesarean delivery BW:3.0 kg      bristling up head:3^+^M sit without help: 7M walk without help: incapable call mom: incapable   normal                                                                                      HC: normal; Hypertonia;                                           EEG (1.2Y): slow wave in sleep stage; EMG: normal;                                                                                                                                                                                               MRI (1Y): diffused abnormal signal in the central deep and subcortical white matter, hyperintense in the T2 sequence and hypointense in T1 and FLAIR sequence; MRS: normal.
  10     VWM                                  Male, 2.4          Seizure; Mental and motor regression;                   G1P1 full-term normal delivery BW:3.0 kg        bristling up head:3M sit without help: 6M walk without help:12M call mom: 12M                   normal                                                                                      HC: normal; Hypertonia; Amyasthnia;                               EEG(2.2Y): Paroxysmal slow wave in REM state; EMG: normal;                                                                                                                                                                                       MRI (2.4Y): abnormal signal in the white matter of frontal lobe, temporal lobe and periventricular, hyperintense in the T2 sequence and hypointense in T1 and FLAIR sequence; MRS show high Cho crest.
  11     MLC                                  Male, 6.0          macrocephalus; seizure; motor retardation               G1P1 full-term normal delivery BW:2.75 kg       bristling up head:3M sit without help: 6M walk without help:14M call mom: 12M                   normal                                                                                      HC: 57 cm(6Y); Hypertonia; Hyperreflexia; Ataxia;                 EEG(6Y): spike waves, sharp waves in REM state, especially in the right temporal lobe;                                                                                                                                                           MRI (6Y): abnormal signal in the white matter of bilateral cerebral hemisphere, hyperintense in the T2 and FLAIR sequence, hypointense in T1 sequence; a 19\*13 mm hypointense of right temporal lobe in FLAIR sequence
  12     MLC                                  Femal, 0.7         macrocephalus; Mental and motor retardation;            G1P1 full-term Cesarean delivery BW:2.8 kg      bristling up head: incapable sit without help: incapable                                        normal                                                                                      HC: 48 cm(8M); Hypotonia; setting sun eye                         EEG(5M): spike waves in REM state, especially in the left temporal lobe;                                                                                                                                                                         MRI(6M): cerebral hemispheric swelling, diffuse abnormal signal in the white matter of bilateral cerebral hemisphere, hyperintense in the T2 and FLAIR sequence, hypointense in T1 sequence; a 10\*12 mm hypointense of left temporal lobe in FLAIR sequence
  13     MLC                                  Male, 1.7          macrocephalus; seizure; Mental and motor retardation;   G4P2 full-term Cesarean delivery BW:2.57 kg     bristling up head:6M sit without help: 12M walk without help: incapable call mom: 12M           normal                                                                                      HC: 45.5 cm(4M); Hypotonia;                                       EEG(1.5M): sharp waves in REM state; EMG: normal;                                                                                                                                                                                                MRI (1.5Y): abnormal signal in the white matter of bilateral cerebral hemisphere, hyperintense in the T2 and FLAIR sequence, hypointense in T1 sequence; a 6\*10 mm hypointense of frontal lobe in FLAIR sequence
  14     GLD                                  Male, 2.8          Mental and motor regression;                            G2P2 full-term Cesarean delivery BW:3.0 kg      bristling up head:3 + M sit without help: 6M walk without help: 18M call mom: 13M               normal                                                                                      HC: normal Hyperreflexia Ataxia;                                  EEG(2.5Y): sharp waves in left frontal, temporal lobe, slow background waves; EMG: normal;                                                                                                                                                       MRI (2.5Y): symmetry cerebral atrophy, abnormal signal in white matter of brainstem, posterior limb of internal capsule and cerebellum
  15     PMD                                  Male, 4.9          Mental and motor regression;                            G2P1 full-term normal delivery BW:3.0 kg        bristling up head:5M sit without help: 14M walk without help: incapable call mom: 13M           normal                                                                                      HC: normal Hyperreflexia Ataxia;                                  VEP: P100 latency increased; BAEP: latency prolonged;                                                                                                                                                                                            MRI (4.5Y): diffuse abnormal signal of white matter, hyperintense in the T2 sequence; MRS: normal.
  16     PMD                                  Male, 2.0          Motor retardation;                                      G1P1 full-term normal delivery BW:3.0 kg        bristling up head:6M sit without help: 12M walk without help: incapable call mom: 12M           normal                                                                                      HC: normal; Hypotonia; Nystagmus;                                 VEP: normal; BAEP: latency prolonged;                                                                                                                                                                                                            MRI (2Y): diffuse abnormal signal of white matter, hyperintense in the T2 sequence; MRS: normal.
  17     X-ALD                                Male, 7            Motor regression                                        G2P2 full-term normal delivery BW:3.1 kg        bristling up head:4M sit without help: 8M walk without help: 15M call mom: 12M                  normal                                                                                      HC: normal; Dark complexion; Hypotonia Knee hyperreflexia         ACTH \> 440.4 pmol/L(normal:1.6-13.9 pmol/L); Cortisol: normal; PRL: 35.59 mg/ml(normal 3.46-19.0 mg/ml); EEG(7Y): slow background wave; VEP: normal; BAEP: normal;                                                                              MRI (7Y): diffuse abnormal signal in callusom and brainstem, hyperintense in the T2 sequence, the signal were intensified in enhanced sequence, "butterfly"-like signal.
  18     X-ALD                                Male, 7            Progressive vision loss; Motor regression;              G4P2 full-term normal delivery BW:3.0 kg        bristling up head:3M sit without help: 7M walk without help: 12M call mom: 12M                  The mother's brother dead at 10 years old for unclear reason                                HC: normal; Dark complexion; Hypotonia Hyperreflexia Ataxia       ACTH, Cortisol, PRL: normal; VEP: normal; BAEP: normal;                                                                                                                                                                                          MRI (6.5Y): diffuse abnormal signal in callusom and brainstem, hyperintense in the T2 sequence,
  19     Zellweger syndrome                   Female, 5.8        developmental retardation                               G1P1 full-term normal delivery BW:2.7 kg        bristling up head:5M sit without help: 12M walk without help: 2Y call mom: 2Y                   normal                                                                                      HC: normal Hypertonia Hyperreflexia Decreased visual;             EEG: slow background activity with spike-and-wave discharge, localized in the right frontal and temporal region; EMG: normal; VEP: normal; BAEP: latency prolonged;                                                                              MRI (5.8Y): abnormal hyperintense in the splenium of corpus callosum, adjacent parieto-occipital white matter, posterior limbs of internal capsules extending to centrum ovale, thalami and upper cervical spinal cord on FLAIR and T2 sequences; Gadolinium enhancement is visible on T1-weighted sequences in internal capsules and anterior commissure.
  20     Alexander disease                    Male, 0.8          Seizure; developmental retardation                      G2P2 full-term Cesarean delivery BW:3.75 kg     bristling up head:5M sit without help: incapable                                                normal                                                                                      HC: 46.5(9M); Hypotonia                                           EEG(9M): sharp wave, slow wave in frontward head; EMG: normal; VEP: normal; BAEP: normal.                                                                                                                                                        MRI (9M): abnormal signal of white matter in frontal and parietal lobe and periventricular, hyperintense in the T2 and FLAIR sequences, hypointense in T1 sequence.

Y = years; M = months; BW = birth weight; HC = head circumference; GDD = global developmental delay; EEG = electroencephalograms; EMG = electromyography; VEP = visual evoked potential; BAEP = brain auditory evoked potentials; MRI = magnetic resonance imaging; FLAIR Sequence = fluid-attenuated inversion recovery sequences; All the acronym of Diagnosis can see in the article.

###### Gene identified by targeted capture and MPS in atypical leukoencephalopathy patients.

  Probands                         Sex, age (years)   Genomic coordinates[a](#t3-fn2){ref-type="fn"}   Reference reads          Variant reads             Mutation gene                   cDNA                       Protein         HGMD reported or not            de novo/inherited                        ExAC_MAF                         1000 genomes                            SIFT                     Mutation Taster         PolyPhen-2 HumVarscore
  ------------------------------- ------------------ ------------------------------------------------ ----------------- ------------------------------ ------------------- ---------------------------------- --------------------- ---------------------- -------------------------------------- -------------------------------- ------------------------------------- -------------------------------- --------------------------- ---------------------------
  1                                     M, 0.9                    chr11:67376961 C \> T                      130                     128                    *NDUFV1*          c.338C \> T (NM_001166102.1)         p.Pro113Leu            Unreported                      Paternal                           0.00004118                             ---                   Deleterious low confidence(0)         Disease causing          Probably damaging (1)
  chr11:67377072 G \> A                  139                               123                            *NDUFV1*       c.449G \> A (NM_001166102.1)      p.Arg150Gln                 Unreported                   Maternal                 ---                            ---                    Deleterious low confidence(0)              Disease causing               Probably damaging (0.989)                                 
  2                                     M, 0.4                    chr15:41688980 T \> C                      178                     190                    *NDUFAF1*          c.278A \> G (NM_016013.3)           p.His93Arg              Reported                       Paternal                              ---                                 ---                         Deleterious (0.01)              Disease causing              Benign(0.043)
  chr15:41689011 C \> T                  125                               115                            *NDUFAF1*       c.247G \> A (NM_016013.3)        p.Asp83Asn                   Reported                    Maternal              0.0000329                         ---                          Deleterious (0.03)                    Polymorphism                       Benign(0.349)                                       
  3                                     F, 3.1                    chr1:161172233 C \> A                      27                       27                    *NDUFS2*          c.58C \> A (NM_001166159.1)          p.Pro20Thr             Unreported                      Maternal                             0.087                              0.0865                  Tolerated low confidence(0.34)    Polymorphism automatic           Benign(0.001)
  chr1:161180394 C \> T                   86                                64                            *NDUFS2*       c.880C \> T (NM_001166159.1)      p.Arg294Trp                 Unreported                   Paternal                 ---                            ---                            Deleterious(0)                     Disease causing                 Probably damaging (1)                                   
  4                                     M, 2.5                    chr22:51065317 A \> G                      60                       64                     *ARSA*           c.371T \> C (NM_001085428.2)         p.Leu124Pro            Unreported                      Paternal                              ---                                 ---                           Deleterious(0)                Disease causing        Probably damaging (0.991)
  chr22:51065757 C \> A                   52                                33                             *ARSA*        c.44G \> T (NM_001085428.2)       p.Gly15Val                  Unreported                   Maternal                 ---                            ---                            Tolerated(0.2)                      Polymorphism                       Benign(0.116)                                       
  5                                      F, 3                  chr22:51063758 -51063759insC                  347                     315                     *ARSA*         c.1087_1088insC (NM_001085428.2)   p.Gly363 Alafs\*124        Unreported                      Maternal                              ---                                 ---                                ---                      Disease causing                   ---
  chr22:51066021 -51066022insCA          196                               188                             *ARSA*        c.187_188insCA (NM_000487.5)   p.Asp63 Alafs\*18              Unreported                   Paternal                 ---                            ---                                 ---                           Disease causing                          ---                                            
  6                                     M, 2.5                    chr22:51065689 C \> T                       0                       47                     *ARSA*            c.370G \> A (NM_000487.5)           p.Gly124Ser             Reported                  Paternal/Maternal                       0.00001668                             ---                         Deleterious (0.01)         Disease causing automatic   Possibly damaging(0.895)
  7                                     M, 2.1                 chr22:51063674-51063674insC                   20                       28                     *ARSA*           c.1170dupC (NM_001085428.2)      p.Ser391 Glnfs\*96         Unreported                      Paternal                              ---                                 ---                                ---                      Disease causing                   ---
  chr22:51065133 C \> T                   38                                21                             *ARSA*         c.740G \> A (NM_000487.5)        p.Gly247Glu                 Unreported                   Maternal                 ---                            ---                            Deleterious(0)                     Disease causing                Probably damaging(0.999)                                 
  8                                     M, 3.5                     chr2:27587620 C \> T                       0                      142                    *EIF2B4*           c.1334G \> A (NM_015636.3)          p.Arg445His             Reported                  Paternal/Maternal                          ---                                 ---                           Deleterious(0)                Disease causing        Probably damaging(0.996)
  9                                     F, 1.2                    chr3:183857908 G \> A                       0                      1136                   *EIF2B5*           c.806G \> A (NM_003907.2)           p.Arg269Gln             Reported                  Paternal/Maternal                          ---                                 ---                         Deleterious (0.04)              Disease causing              Benign(0.402)
  10                                    M, 2.4                    chr3:183858366 G \> C                      417                     549                    *EIF2B5*           c.1004G \> C (NM_003907.2)          p.Cys335Ser             Reported                       Paternal                              ---                                 ---                          Tolerated (0.23)               Disease causing              Benign(0.084)
  chr3:183860329 A \> G                  1001                              796                            *EIF2B5*        c.1484A \> G (NM_003907.2)       p.Tyr495Cys                  Reported                    Maternal             0.000008326                        ---                            Deleterious(0)           Disease causing automatic automatic      Possibly damaging(0.621)                                 
  11                                     M, 6                   chr22:50502592-50502599del                    3                       3                      *MLC1*            c.924_929del (NM_139202.2)      p.Leu309_Leu310del          Reported                       Paternal                              ---                                 ---                                ---                       polymorphism                     ---
  chr22:50521562 G \> A                   70                                94                             *MLC1*         c.218G \> A (NM_015166.3)        p.Gly73Glu                   Reported                    Maternal                 ---                            ---                    Deleterious low confidence (0)             Disease causing                  Probably damaging(1)                                   
  12                                    F, 0.7                    chr22:50521562 C \> T                       0                       88                     *MLC1*            c.218G \> A (NM_015166.3)           p.Gly73Glu              Reported                       Paternal                              ---                                 ---                   Deleterious low confidence (0)        Disease causing          Probably damaging(1)
  13                                    M, 1.7                    chr22:50521562 C \> T                       0                      388                     *MLC1*             c.218G \> A(NM_015166.3)           p.Gly73Glu              Reported                  Paternal/Maternal                          ---                                 ---                   Deleterious low confidence (0)        Disease causing          Probably damaging(1)
  14                                    M, 2.8                    chr14:88411981 G \> A                      53                       33                     *GALC*            c.1586C \> T (NM_000153.3)          p.Thr529Met             Reported         *De novo*[b](#t3-fn3){ref-type="fn"}            0.000066225                             ---                         Deleterious (0.01)              Disease causing        Probably damaging (0.995)
  chr14:88417067 G \> A                   29                                33                             *GALC*          c.1187G \> A (NM_000153)          p.R396Q                   Unreported                   Paternal                 ---                            ---                            Deleterious(0)                     Disease causing               Probably damaging (0.962)                                 
  15                                    M, 4.9                         Duplication                            /                       /                      *PLP1*                        /                            /                  Reported                      *De novo*                              ---                                 ---                                ---                                                        ---
  16                                     M, 2                     chrX:103043377 T \> C                       0                      348                     *PLP1*            c.634T \> C (NM_000533.4)           p.Trp212Arg             Reported                       Maternal                              ---                                 ---                           Deleterious(0)                Disease causing        Probably damaging (0.999)
  17                                     M, 7                     chrX:153002662 T \> A                       0                       33                     *ABCD1*           c.1445T \> A (NM_000033.3)          p.Val482Asp            Unreported                     *De novo*                              ---                                 ---                           Deleterious(0)                Disease causing              Benign(0.013)
  18                                     M, 7                     chrX:152991011 A \> C                       5                      181                     *ABCD1*           c.290A \> C (NM_000033.3)           p.His97Pro              Reported                       Maternal                              ---                                 ---                           Deleterious(0)                Disease causing        Probably damaging (0.99)
  19                                    F, 5.8                     chr6:42932599 G \> A                      59                       62                     *PEX6*            c.2735C \> T (NM_000287.3)          p.Ala912Val            Unreported                      Paternal                          0.000008326                             ---                           Deleterious(0)                Disease causing          Probably damaging (1)
  chr6:42937459: 42insT                   38                                26                             *PEX6*          c.1313dupT (NM_000287.3)     p.Glu439 Glyfs\*6              Unreported                   Maternal             0.000008327                        ---                                 ---                           Disease causing                          ---                                            
  20                                    M, 0.8                    chr17:42992605 T \> A                      63                       33                     *GFAP*           c.250A \> T (NM_001131019.2)         p.Ile84Phe             Unreported                     *De novo*                              ---                                 ---                           Deleterious(0)                Disease causing        Probably damaging (0.97)

F = Female; M = Male; cDNA = complementary DNA; HGMD = The human gene mutation database.

^a^hg19.

^b^It's not sure whether the de *novo* mutation in patient 14 was in maternal allele or not.

[^1]: These authors contributed equally to this work.
